Noboru Shibasaki
Papers
1
Total Citations
4
H-Index
1
About
Noboru Shibasaki is a leading urologic oncologist whose research focuses on optimizing treatment strategies for high-risk and very high-risk prostate cancer. His major contributions lie in refining neoadjuvant chemohormonal therapy, particularly investigating the role of degarelix acetate combined with low-dose estramustine phosphate prior to robot-assisted radical prostatectomy. A key finding from his work is that dose compliance with estramustine phosphate in this regimen serves as a significant predictor of biochemical recurrence, offering a practical metric for personalizing therapy. His 2024 study on this topic, which has already garnered 4 citations, underscores the clinical relevance of his research in improving outcomes for patients with aggressive disease. By bridging the gap between pharmacological adherence and surgical oncology, Shibasaki’s work provides actionable insights for clinicians aiming to reduce recurrence risks. His contributions are particularly valuable for researchers and students interested in the intersection of drug compliance, neoadjuvant protocols, and precision medicine in prostate cancer management.
Research Focus
Key Achievements
Top Papers
- 1